Volume : 09, Issue : 12, December – 2022
Title:
04.ROLE OF URSODEOXYCHOLIC ACID IN MANAGEMENT OF INDIRECT HYPERBILIRUBINEMIA
Authors :
Hussain abdullah alsharif, Maher foutial obaid alqathami, Humied Turibish Alnafei, Ahmed Nassar Alghamdi, Hani Hashem Shanwaz, HANI JAMAL BAZ, Yaser Saeed Othman ALsadi, Mohammed Abdullah Allehyani, sami salah alkhttabi, Ahmad Fouad Alyamani
Abstract :
Hyperbilirubinemia is a common newborn condition. The purpose of this study was to examine the effect of ursodeoxycholic acid (UDCA) on infants with indirect hyperbilirubinemia.
In neonates with indirect hyperbilirubinemia, ursodeoxycholic acid had additive effects with phototherapy. Ursodeoxycholic acid could be considered as a novel adjuvant therapy for neonatal indirect hyperbilirubinemia in order to decrease the mean total serum bilirubin and shorten the duration of phototherapy. Hyperbilirubinemia is a common newborn condition. The purpose of this study was to examine the effect of ursodeoxycholic acid (UDCA) on infants with indirect hyperbilirubinemia.
In neonates with indirect hyperbilirubinemia, ursodeoxycholic acid had additive effects with phototherapy. Ursodeoxycholic acid could be considered as a novel adjuvant therapy for neonatal indirect hyperbilirubinemia in order to decrease the mean total serum bilirubin and shorten the duration of phototherapy.UDCA is considered an effective complementary therapeutic ad-
which renders this drug an excellent choice in neonatal indirect hy-
UDCA is considered an effective complementary therapeutic ad-
which renders this drug an excellent choice in neonatal indirect hy-
UDCA is considered an effective complementary therapeutic ad-
which renders this drug an excellent choice in neonatal indirect hy-
UDCA is considered an effective complementary therapeutic ad-
which renders this drug an excellent choice in neonatal indirect hy-
UDCA is considered an effective complementary therapeutic ad-
which renders this drug an excellent choice in neonatal indirect hy-
Hyperbilirubinemia is a common new-born condition. The purpose of this study was to examine the effect of ursodeoxycholic acid (UDCA) on infants with indirect hyperbilirubinemia. We have conducted a narrative review through electronic databases; PUBMED, EMBASE, for all relevant studies that were published up to 2022. In neonates with indirect hyperbilirubinemia, ursodeoxycholic acid had additive effects with phototherapy. Ursodeoxycholic acid could be considered as a novel adjuvant therapy for neonatal indirect hyperbilirubinemia in order to decrease the mean total serum bilirubin and shorten the duration of phototherapy.
Cite This Article:
Please cite this article in press Hussain abdullah alsharif et al, Role Of Ursodeoxycholic Acid In Management Of Indirect Hyperbilirubinemia., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
2. Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015;2015:0319.
3. Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics. 2009;124:1031–39. doi: 10.1542/peds.2008-2980.
4. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114:297–316.
5. Kumar P, Chawla D, Deorari A. Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates. Cochrane Database Syst Rev. 2011;2011:CD007969.
6. Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice. N Engl J Med. 2008;358:920–8.
7. Stokowski LA. Fundamentals of phototherapy for neonatal jaundice. Adv Neonatal Care. 2011;11(5 Suppl):S10–S21.
8. Honar N, Ghashghaei Saadi E, Saki F, Pishva N, Shakibazad N, Hosseini Teshnizi S, et al. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. J Pediatr Gastroenterol Nutr. 2016;62:97–100.
9. Shahramian I, Tabrizian K, Ostadrahimi P, Afshari M, Soleymanifar M, Bazi A. Therapeutic effects of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a randomized double-blind clinical trial. Arch Anesth Crit Care. 2019;5:99–103.
10. Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterol. 1996;111:716–719.
11. Willot S, Uhlen S, Michaud L, Briand G, Bonnevalle M, Sfeir R, et al. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics. 2008;122:e1236–e1241.
12. Akefi R, Hashemi SM, Alinejad S, Almasi-Hashiani A. The effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy: a randomized clinical trial. J Matern Fetal Neonatal Med. 2020.
13. Cuperus FJC, Hafkamp AM, Havinga R, Vitek L, Zelenka J, Tiribelli C, et al. Effective treatment of unconjugated hyperbilirubinemia with oral bile salts in Gunn rats. Gastroenterology. 2009;136(2):673–682.
14. Tiribelli C, Ostrow JD. Intestinal flora and bilirubin. J Hepatol. 2005;42(2):170–172.
15. Vítek L, Carey MC. Enterohepatic cycling of bilirubin as a cause of “black” pigment gallstones in adult life. Eur J Clin Invest. 2003;33(9):799–810.
16. Lazarus G, Francie J, Roeslani RD, Saldi SRF, Oswari H. Role of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a systematic review and meta-analysis of randomized controlled trials. Ital J Pediatr. 2022 Oct 17;48(1):179.
17. Auger N, Laverdière C, Ayoub A, Lo E, Luu TM. Neonatal phototherapy and future risk of childhood cancer. Int J Cancer. 2019;145:2061–2069.
18. Oláh J, Tóth-Molnár E, Kemény L, Csoma Z. Long-term hazards of neonatal blue-light phototherapy. Br J Dermatol. 2013;169:243–249.
19. Maimburg RD, Olsen J, Sun Y. Neonatal hyperbilirubinemia and the risk of febrile seizures and childhood epilepsy. Epilepsy Res. 2016;124:67–72.
20. Newman TB, Wu YW, Kuzniewicz MW, Grimes BA, McCulloch CE. Childhood seizures after phototherapy. Pediatrics. 2018;142:e20180648.
21. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Semin Neonatol 2002; 7:111–119.
22. Chawla D, Parmar V. Phenobarbitone for prevention and treatment of unconjugated hyperbilirubinemia in preterm neonates: a systematic review and meta-analysis. Indian Pediatr 2010; 47:401–407.
23. Méndez-Sánchez N, Brink MA, Paigen B, et al Ursodeoxycholic acid and cholesterol induce enterohepatic cycling of bilirubin in rodents. Gastroenterology 1998; 115:722–732.
24. Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 1997; 24:573–589.
25. Schwartz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia: current guidelines and emerging therapies. Pediatr Emerg Care 2011; 27:884–889.
26. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36:525–531.
27. Najib KS, Saki F, Hemmati F, et al Incidence, risk factors and causes of severe neonatal hyperbilirubinemia in the South of Iran (Fars Province). Iran Red Crescent Med J 2013; 15:260–263.
28. Shahramian I, Tabrizian K, Ostadrahimi P, Afshari M, Soleymanifar M, Bazi A. Therapeutic effects of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a randomized double-blind clinical trial. Arch Anesth Crit Care. 2019;5:99–103. #
29. El-Gendy FM, Bahbaha WA, Al Kaforyb EE. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. Menoufia Med J. 2019;32:1059–1063.
30. Gharehbaghi MM, Sani AM, Refeey M. Evaluating the effects of different doses of ursodeoxycholic acid on neonatal jaundice. Turk J Pediatr. 2020;62:424–430.
31. Honar N, Ghashghaei Saadi E, Saki F, et al. Effect of ursodeoxycholic acid on indirect hyperbilirubinemia in neonates treated with phototherapy. J Pediatr Gastroenterol Nutr. 2016;62(1):97–100.
32. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316.